Sierra Oncology (SRRA) Stock Price, News & Analysis

Company Overview

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

Key Stats

• Today's Range: $54.99 to $54.99
• 50-Day Range: $54.73 to $54.99
• 52-Week Range: $14.91 to $55.19
• Volume: N/A
• Average Volume: 931,731 shs
• Market Capitalization: $1.34 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SRRA Stock Analysis - Frequently Asked Questions

How were Sierra Oncology's earnings last quarter?

Sierra Oncology, Inc. (NASDAQ:SRRA) issued its quarterly earnings data on Friday, November, 5th. The biotechnology company reported ($2.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.78) by $0.32.

What other stocks do shareholders of Sierra Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sierra Oncology investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), T2 Biosystems (TTOO), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), Trevena (TRVN) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 11/05/2021
• Today: 6/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SRRA
• Previous Symbol: NASDAQ:DNAI
• CIK: 1290149
• Web: www.sierraoncology.com
• Phone: (604) 558-6536
• Fax: N/A
• Employees: 109
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($6.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$94.66 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -111.88%
• Return on Assets: -100.01%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 21.27
• Quick Ratio: 21.27

Sales & Book Value

• Annual Sales: $300 thousand
• Price / Sales: 4,476.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.16 per share
• Price / Book: 8.93

Miscellaneous

• Outstanding Shares: 24,419,000
• Free Float: 13,650,000
• Market Cap: $1.34 billion
• Optionable: Optionable
• Beta: 0.03